The latest trading day saw Eli Lilly (LLY) settling at $770.64, representing a +1.04% change from its previous close.

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

In the closing of the recent trading day, Eli Lilly (LLY) stood at $807.58, denoting a -1.44% move from the preceding trading day.

Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions.

Sixty-three percent of patients starting on Novo Nordisk's Wegovy or Eli Lilly's Zepbound during the first quarter of 2024 ...

Get instant access to a free live Euronext 3X Short Eli Lilly streaming chart. The chart is intuitive yet powerful, customize the chart type to view candlestick patterns, area, line graph style ...

Galcanezumab shows similar pregnancy outcomes to placebo, highlighting the need for more real-world safety data in patients ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for obesity and lifestyle drugs ...

Trump has threatened that pharmaceutical import tariffs could clock in at “25% or higher.” The President first floated the ...